SCL Science

SCL Science Pre-Tax Margin

The Pre-Tax Profit Margin of SCL Science (246960.KQ) as of Nov 18, 2026 is -21.68 %. In the previous year, Pre-Tax Profit Margin was -78.73 % — a change of -72.47% (higher).

Pre-Tax Margin

-21.68 %

YoY

-72.47%

Last updated:

Pre-Tax Profit Margin of SCL Science is 2025 -21.68 % . Pre-Tax Profit Margin of SCL Science was 2024 -78.73 % . It decreases by -72.47% higher compared to the previous year.

The SCL Science Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-502.60 KRW
Jan 1, 2019
-575.73 KRW
Jan 1, 2020
-551.65 KRW
Jan 1, 2021
-988.28 KRW
Jan 1, 2022
-1,618.38 KRW
Jan 1, 2023
-379.96 KRW
Jan 1, 2024
-78.73 KRW
Jan 1, 2025
-21.68 KRW
The SCL Science Pre-Tax Margin history
YEARPre-Tax MarginYoY
-21.68 %-72.47%
-78.73 %-79.28%
-379.96 %-76.52%
-1,618.38 %+63.76%
-988.28 %+79.15%
-551.65 %-4.18%
-575.73 %+14.55%
-502.60 %-66.17%
-1,485.79 %+92.20%
-773.06 %-97.81%
-35,365.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Pre-Tax Profit Margin of SCL Science is -21.68 % in 2025.

Pre-Tax Profit Margin of SCL Science changed from -78.73 % to -21.68 %, representing a -72.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin SCL Science since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's SCL Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SCL Science

All Key Metrics — SCL Science